30 04, 2019

TAmiRNA and advanceCOR receive Eurostars project “thrombomiR”

2019-12-09T09:21:00+01:00April 30th, 2019|biomarkers, drug development, drug discovery, microRNAs, Personalized medicine, safety, thrombomiR|0 Comments

TAmiRNA and advanceCOR, a drug developing biotechnology company which focuses on personalized medicine in cardiovascular diseases, receive Eurostars project entitled: ”A novel microRNA-based platelet function biomarker for personalized anti-thrombotic treatment”.  The aim of the Eurostars project is to validate the use of the thrombomiR™ kit for management of anti-thrombotic therapies. The thrombomiR™ kit is a minimally invasive blood test that can determine changes in platelets reactivity (for example due to a therapy), based on the quantitative analysis of microRNAs, Specifically, the thrombomiR™ kit allows the targeted detection and quantitation of platelet-specific microRNAs in blood plasma. The concentration of these microRNAs increases in the course of activation of platelets and decreases as a result of therapeutic inactivation. Thus, [...]

30 03, 2019

Predicting Postoperative Liver Dysfunction Based on Blood Derived MicroRNA Signatures.

2019-12-09T09:19:55+01:00March 30th, 2019|biomarker, Liver disease, microRNAs, Personalized medicine|0 Comments

We want to draw your attention to the latest publication of the Department of Surgery, Medical University of Vienna, in cooperation with TAmiRNA GmbH, in Hepatology. "Predicting Postoperative Liver Dysfunction Based on Blood Derived MicroRNA Signatures." Hepatology. 2019 Jun;69(6):2636-2651. Personalized medicine in liver surgery. Together with colleagues from Medical University Vienna we could show that plasma levels of three miRNAs can accurately predict liver dysfunction prior to surgery. This will allow us to stratify patients into risk groups that need preoperative liver volume augmentation or might even be better off with alternative treatment options. Click here to read the study

30 01, 2019

Ask the Expert: kit or service, NGS or qPCR – what is the best choice for my microRNA biomarker project?

2019-12-09T09:19:33+01:00January 30th, 2019|biomarkers, exosomes, liquid biopsies, LMD, microRNA services, microRNAs, osteomiR, thrombomiR|0 Comments

Can't find the answer to your question on our site? Not sure which method is right for your research? Get in touch with our experts at TAmiRNA - they will answer your questions and help to move from your ideas to results. Get in touch

8 08, 2018

Eager to learn more about TAmiRNA qPCR kits and the exciting field of microRNAs?

2019-12-09T09:18:58+01:00August 8th, 2018|biomarker, liquid biopsies, microRNAs, osteomiR, thrombomiR|0 Comments

Click here to read our Technotes

16 07, 2018

TAmiRNA receives FFG EARLY STAGE for the development of novel theranostic solutions based on microRNA biomarkers – the PATH project.

2019-12-09T09:18:35+01:00July 16th, 2018|biomarkers, exosomes, liquid biopsies, microRNAs|0 Comments

PATH stands for "Project for Advancing the Application of MicroRNAs as THeranostic Biomarkers". The aim of this project is to create optimal framework conditions for successful research and development of the application of microRNAs as theranostic biomarkers. “Theranostics” means the increasingly close integration of diagnostics and therapy. The aim of theranostics is to enable the right therapy for the right patient at the right time. A biomarker generally refers to a measurable indicator of a biological state or condition. MicroRNAs are a new class of biomarkers with enormous potential for applications in theranostics. They are short regulatory RNA molecules that are essential for the proper function of cells and tissues. The development of diseases is mostly due [...]

16 05, 2018

Improving Quality Of Life For Patients With Osteoporosis Using MicroRNAs

2019-12-09T09:18:10+01:00May 16th, 2018|aging, biomarker, biomarkers, bone fracture risk assessment, microRNAs, osteomiR|0 Comments

We want to draw your attention to our latest article “Improving Quality Of Life For Patients With Osteoporosis Using MicroRNAs” Our simulations provide evidence for the utility of the osteomiR™ test for fracture risk assessment, and, furthermore, highlight the general potential of circulating microRNAs to be exploited as minimal-invasive diagnostic tools. Click here to read the study

27 04, 2018

New evidence for associations between miRNAs and metabolic unhealthy conditions

2019-10-16T09:22:36+02:00April 27th, 2018|aging, biomarker, biomarkers, microRNAs|0 Comments

We want to draw your attention to the latest publication in cooperation with TAmiRNA GmbH, in Obesity Surgery.” Reduction of Premature Aging Markers After Gastric Bypass Surgery in Morbidly Obese Patients.” The findings indicate a significant reduction of the proinflammatory SASP after bariatric surgery. An increase in telomere length and reduced oxidative stress at telomeres was observed. Moreover, miR10a-5p which is downregulated during aging was upregulated after surgery. Click here to read the study

21 03, 2018

Serum levels of bone-related microRNAs and their association to bone microstructure and histomorphometry

2019-10-16T09:22:50+02:00March 21st, 2018|biomarker, bone diseases, microRNAs, microstructure, standard tools|0 Comments

We want to draw your attention to the latest publication of the VINFORCE research Group in cooperation with TAmiRNA GmbH, in Scientific Reports from Nature. “Bone-related circulating microRNAs miR-29b-3p, miR-550a-3p, and miR-324-3p and their association to bone microstructure and histomorphometry.” Scientific Reports, Volume 8,4867 (2018) MicroRNAs are promising new biomarkers for bone diseases. The findings enhance the potential value of circulating miRNAs as bone biomarkers and the clinical utility of miRNAs to reflect dynamic changes in bone formation and microstructure. Click here to read the study

23 01, 2018

TAmiRNA & Vivomicx announce the introduction of new technology to make preclinical drug discovery and drug development more efficient.

2019-12-09T09:17:20+01:00January 23rd, 2018|biomarkers, drug development, drug discovery, LMD, microRNA, microRNAs, Vivomicx|0 Comments

TAmiRNA & Vivomicx have combined their technologies of laser microdissection and high sensitivity qPCR, which enables the quantitative analysis of cell-type specific RNA expression in complex tissues. Using this protocol TAmiRNA & Vivomicx have already been able to demonstrate: the profound difference of RNA expression between whole tumor and subsets of cells within the tumor and the large heterogeneity in RNA expression between colorectal* tumor compartments such as tumor, stroma and tumor endothelial cells. * Note: the technology can be utilized for almost any tissue sample. The combination of Vivomicx and TAmiRNA´s proprietary protocols is clearly superior to the current standard where only whole tumor material is analyzed, and marks another step on the road to make the [...]

10 01, 2018

New evidence that microRNA bone biomarkers can improve early diagnosis of osteoporosis

2019-10-16T09:23:20+02:00January 10th, 2018|bone fracture risk assessment, female, microRNA, microRNAs, standard tools|0 Comments

We would like to draw your attention to our lastest publication: “Cost-utility analysis of fracture risk assessment using microRNA compared with Standard Tools and no Monitoring in the Austrian female Population.” Bone. Volume 108, 2018; Pages 44-54. This study presents the first comprehensive attempt to model the cost-effectiveness of circulating microRNAs for bone fracture risk assessment in a central European female post-menopausal population in comparison to DXA and FRAX®. The results demonstrate that the osteomiR™ test can be a cost-effective alternative to established risk assessment strategies. Click here to read the study